Investment Objective
To achieve long-term capital appreciation over five years or more and an income, through a diversified portfolio of UK companies. The Amity UK Fund aims to invest at least 80% in UK companies whose primary listing is in the UK by investing in a portfolio of companies which make a positive contribution to society and the environment through sustainable and socially responsible practices.

Fund Manager
Manager name: Sue Round
Start Date: 01/03/1988
Manager name: Ketan Patel
Start Date: 01/09/2016

Price Information
Single price: 422.90p (as at 30/09/2020)
Currency: British Pound
Pricing: Daily
Historic Yield (%)*: 1.90

Fund Facts
Fund Size: £119.23m
IA Sector: IA UK All Companies
Index**: FTSE All Share
Asset Class: Equity
Launch Date: 01/03/1988
Domicile: United Kingdom
Number of Holdings: 67

Identifiers
Sedol: 0937238
ISIN: GB0009372383

Dividends
Ex-Dividend Date: 01/01, 01/07
Dividend Pay Date: 30/04, 31/08

Charges
AMC*: 1.25%
Ongoing Charge: 1.29%
Initial Charge: 5.00%

Fund Manager Commentary
September saw the FTSE 100, FTSE 250 and FTSE Small Cap return -1.6%, -2.7% and -1.4% respectively. The Prime Minister announced new lockdown measures due to the rapid spread of coronavirus. The chancellor announced that the autumn budget had been cancelled, as well as the extension of various government support measures and a new job support scheme. The Monetary Policy Committee unanimously voted to hold interest rates and the level of quantitative easing steady whilst suggesting that negative interest rates could be a policy tool going forward. The government introduced an Internal Market Bill which caused tensions within both the Conservative party and the EU. This again raised the prospect again of a no deal exit, whilst Sterling fell against the US dollar largely due to this. At a stock level, Genus, DS Smith and Halma contributed to outperformance, whilst detractors included Legal & General, Morgan Sindall and Applied Graphene. At a sector level, the underweight to banks, zero exposure to oil & gas and overweight to pharmaceuticals were tailwinds for outperformance, whilst the zero exposure to tobacco and overweight to general retailers acted as a drag. Regarding portfolio activity, we increased positions in Sabre Insurance, James Fisher and Clinigen.

Cumulative Performance (as at 30/09/2020)

<table>
<thead>
<tr>
<th></th>
<th>1m</th>
<th>3m</th>
<th>6m</th>
<th>1y</th>
<th>3y</th>
<th>5y</th>
<th>10y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund</td>
<td>-0.89%</td>
<td>-0.77%</td>
<td>12.98%</td>
<td>-8.17%</td>
<td>-5.50%</td>
<td>11.79%</td>
<td>87.12%</td>
</tr>
<tr>
<td>Sector</td>
<td>-1.76%</td>
<td>-0.95%</td>
<td>13.07%</td>
<td>-12.76%</td>
<td>-7.95%</td>
<td>16.90%</td>
<td>72.39%</td>
</tr>
</tbody>
</table>

Discrete Performance (as at 31/12/2019)

<table>
<thead>
<tr>
<th></th>
<th>31/12/2014 to 31/12/2015</th>
<th>31/12/2015 to 31/12/2016</th>
<th>31/12/2016 to 31/12/2017</th>
<th>31/12/2017 to 31/12/2018</th>
<th>31/12/2018 to 31/12/2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund</td>
<td>7.93%</td>
<td>3.93%</td>
<td>12.24%</td>
<td>-12.66%</td>
<td>26.00%</td>
</tr>
<tr>
<td>Sector</td>
<td>4.86%</td>
<td>10.82%</td>
<td>13.99%</td>
<td>-11.19%</td>
<td>22.24%</td>
</tr>
</tbody>
</table>

Source: FE fundinfo. Fund and Sector performance is shown in local currency, on a bid to bid basis with income re-invested into the fund.
Top 10 Holdings

<table>
<thead>
<tr>
<th>Name</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>HALMA ORD GBP0.10</td>
<td>5.91%</td>
</tr>
<tr>
<td>DECHRA PHARMA ORD GBP0.01</td>
<td>4.79%</td>
</tr>
<tr>
<td>GENUS ORD GBP0.10</td>
<td>3.71%</td>
</tr>
<tr>
<td>DUNELM GROUP LTD W1</td>
<td>3.62%</td>
</tr>
<tr>
<td>RENTOKIL INITIAL ORD GBP0.01</td>
<td>3.19%</td>
</tr>
<tr>
<td>GLAXOSMITHKLINE ORD GBP0.25</td>
<td>2.83%</td>
</tr>
<tr>
<td>SMITH &amp; NEPHEW ORD USD0.20</td>
<td>2.71%</td>
</tr>
<tr>
<td>NEXT ORD GBP0.10</td>
<td>2.71%</td>
</tr>
<tr>
<td>ASTRazeneca ORD USD0.25</td>
<td>2.68%</td>
</tr>
<tr>
<td>SMITH(DS) ORD GBP0.10</td>
<td>2.42%</td>
</tr>
</tbody>
</table>

Ratings and Awards

FE fundinfo Crown Rating: Rayner Spencer Mills Rating:

Contact Information

EdenTree Investment Management
PO Box 3733
Swindon
SN4 4BG

Investment professionals – 0800 011 3821
Private individuals – 0800 358 3010
Charity fund enquiries – 0800 032 3778

www.edentreeim.com

*Past 12 months’ distributions as a % of midshare price, excluding preliminary charge.
Yield figures are as at 30/09/2020.
**We compare the fund’s performance to the FTSE All Share Index, however the portfolio manager is not bound or influenced by the index when making investment decisions.
Past performance should not be seen as a guide to future performance. The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations, you may not get back the amount originally invested.
This factsheet should not be interpreted as financial advice. If you are unsure which investment is most suited for you, the advice of a qualified financial adviser should be sought.
EdenTree Investment Management Limited (EdenTree) Reg. No. 2519319. Registered in England at Beaufort House, Brunswick Road, Gloucester, GL1 1JZ, United Kingdom. EdenTree is authorised and regulated by the Financial Conduct Authority and is a member of the Investment Association. Firm Reference Number 527473.